Barinthus Biotherapeutics plc. — Form 8-K
Filed September 1, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
Barinthus Biotherapeutics plc. (market cap ~$13.7M) filed an 8-K on 2026-09-01 reporting Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The filing provides no specific details regarding which exchange, which listing rule was violated, timeline, or remediation steps. Item 8.01 (Other Events) is also referenced but no substantive disclosure is provided in the abstract.
Why this rating
Delisting threat is existential for a micro-cap biotech. Loss of exchange listing destroys liquidity, investor access, and credibility—potentially fatal for fundraising and business continuity.
Extracted items
- 3.01 delisting notice
- 8.01 other event
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $0.75 ▼ 1.95% | at our read · unknown $0.77 | +10 min · unknown $0.77 ▲ 0.00% | +30 min · unknown $0.77 ▲ 0.00% | +1 hr · unknown $0.77 ▲ 0.00% | +4 hrs pending |
The stock had already moved +1.99% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.